90Y ibritumomab tiuxetan (Zevalin) radioimmuntherapy does not preclude effective delivery of subsequent therapy for lymphoma - Schilder, RJ; Witzig, T; Gordon, L (Proc Am Soc Clin Oncol, 2002)
(1064).